SK Bioscience is set to accelerate the late-stage clinical trials for its advanced **pneumococcus vaccine** candidate, leveraging significant support from a **South Korean government fund** totaling 300 billion won ($200 million).
The prominent vaccine developer, **SK Bioscience** (the vaccine arm of SK Group), announced Friday that its board of directors has approved an ultra-low interest loan from the government-backed **National Growth Fund**. This crucial decision follows the Fund Operations Committee’s nomination of **SK Bioscience** as a recipient on Thursday, underscoring confidence in the company’s biotechnology advancements.
The **National Growth Fund** represents a strategic public-private financial initiative specifically designed to cultivate key industries vital for national competitiveness. These include cutting-edge sectors such as artificial intelligence, semiconductors, biotechnology, and secondary cells. Through a citizen-participatory funding model, the fund channels essential capital into future-oriented industries and major projects poised to boost global competitiveness.
**SK Bioscience** will strategically allocate these funds towards the ongoing research and development (R&D) of **GBP410**. This innovative 21-valent **pneumococcal conjugate vaccine candidate** is designed to offer expanded serotype coverage, a significant improvement over previous commercialized versions of similar vaccines.
Developed in partnership with global pharmaceutical leader Sanofi, this promising **vaccine candidate** is currently progressing through **Phase 3 clinical trials**. **SK Bioscience** aims to release top-line data for the **GBP410 pneumococcal vaccine** in the second half of 2027, as it simultaneously advances comprehensive plans for its manufacturing and subsequent commercialization.
“The government’s decision to provide substantial support for this project unequivocally acknowledges our robust R&D capabilities and global competence in vaccine development,” stated **SK Bioscience** CEO Ahn Jae-yong.
CEO Ahn Jae-yong further emphasized, “Our commitment to investing in key drug pipelines and essential infrastructure will continue, fortifying **South Korea’s vaccine sovereignty** and ensuring robust preparedness for future infectious diseases globally.”
shwang9
